Atlas Trials

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Clinical trial NCT06869239 · RECRUITING

Trial details

NCT number
NCT06869239
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Study type
OBSERVATIONAL
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Start date
2025-02-25
Primary completion
2027-01-03
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.